Yuk Pheel Park1, Linchun Jin2, Katie B Bennett1, Dunrui Wang3, Kristianna M Fredenburg4, Jennifer E Tseng5, Lung-Ji Chang6, Jianping Huang7, Edward K L Chan8. 1. Department of Oral Biology, University of Florida, Gainesville, FL 32610, USA. 2. Department of Neurosurgery, University of Florida, Gainesville, FL 32610, USA; Fourth Section of the Department of Neurosurgery, The First Affiliated Hospital, Harbin Medical University (HMU), Harbin, China. 3. Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, MD 20892, USA. 4. Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA. 5. UF Health Cancer Center-Orlando Health, Orlando, FL 32806, USA. 6. Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA. Electronic address: lchang@mgm.ufl.edu. 7. Department of Neurosurgery, University of Florida, Gainesville, FL 32610, USA. Electronic address: jianping.huang@neurosurgery.ufl.edu. 8. Department of Oral Biology, University of Florida, Gainesville, FL 32610, USA. Electronic address: echan@ufl.edu.
Abstract
OBJECTIVES: In accordance with the Precision Medicine Initiative, new treatment strategies for head and neck squamous cell carcinoma (HNSCC) are needed to yield better therapeutic outcomes. The purpose of this study was to establish and validate chimeric antigen receptor (CAR)-T cells targets in HNSCC. METHODS: Putative CAR-T antigens were identified in The Cancer Genome Atlas database. To validate antigen suitability, quantitative RT-PCR, flow cytometry, and immunofluorescent staining were performed. A retroviral human CD70 CAR construct, using truncated CD27 conjugated with 4-1BB and CD3-zeta costimulatory molecules, was used to transduce activated human T cells to generate CD70 CAR-T cells. Cell-based cytotoxicity and cytokine ELISAs were used to measure efficacy of killing. RESULTS: Nine potential CAR-T targets (CD276, EGFR, MICA, MICB, MAGE-A4, FAP, EPCAM, CD70, B4GALNT1) were identified based on their high expression in tumors compared to flanking control tissues. CD70 was selected for further proof-of-principle analysis based on its differential expression in several tumor subtypes, and showed substantial heterogeneity in individual tumors analyzed. Cell surface CD70 protein and CD70 mRNA were detected from low to high levels in established HNSCC cancer cell lines. CD70 was highly expressed in 4 of 21 tumor biopsies (19%), and 3 of 4 specimens showed strong CD70 expression on the tumor cell surface. CD70-specific CAR-T cells were generated and further demonstrated to recognize and kill CD70-positive HNSCC cells efficiently, but not CD70-negative cancer cells. CONCLUSION: CD70-specific CAR-T cells specifically recognized and efficiently eliminated CD70-positive HNSCC cells. This study provides the basis for further investigation into CD70 and other CAR-T targets.
OBJECTIVES: In accordance with the Precision Medicine Initiative, new treatment strategies for head and neck squamous cell carcinoma (HNSCC) are needed to yield better therapeutic outcomes. The purpose of this study was to establish and validate chimeric antigen receptor (CAR)-T cells targets in HNSCC. METHODS: Putative CAR-T antigens were identified in The Cancer Genome Atlas database. To validate antigen suitability, quantitative RT-PCR, flow cytometry, and immunofluorescent staining were performed. A retroviral humanCD70CAR construct, using truncated CD27 conjugated with 4-1BB and CD3-zeta costimulatory molecules, was used to transduce activated human T cells to generate CD70CAR-T cells. Cell-based cytotoxicity and cytokine ELISAs were used to measure efficacy of killing. RESULTS: Nine potential CAR-T targets (CD276, EGFR, MICA, MICB, MAGE-A4, FAP, EPCAM, CD70, B4GALNT1) were identified based on their high expression in tumors compared to flanking control tissues. CD70 was selected for further proof-of-principle analysis based on its differential expression in several tumor subtypes, and showed substantial heterogeneity in individual tumors analyzed. Cell surface CD70 protein and CD70 mRNA were detected from low to high levels in established HNSCC cancer cell lines. CD70 was highly expressed in 4 of 21 tumor biopsies (19%), and 3 of 4 specimens showed strong CD70 expression on the tumor cell surface. CD70-specific CAR-T cells were generated and further demonstrated to recognize and kill CD70-positive HNSCC cells efficiently, but not CD70-negative cancer cells. CONCLUSION:CD70-specific CAR-T cells specifically recognized and efficiently eliminated CD70-positive HNSCC cells. This study provides the basis for further investigation into CD70 and other CAR-T targets.
Authors: Jianping Huang; Keith W Kerstann; Mojgan Ahmadzadeh; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins Journal: J Immunol Date: 2006-06-15 Impact factor: 5.422
Authors: Qiong J Wang; Zhiya Yu; Ken-Ichi Hanada; Krishna Patel; David Kleiner; Nicholas P Restifo; James C Yang Journal: Clin Cancer Res Date: 2016-11-01 Impact factor: 12.531
Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg Journal: Blood Date: 2010-07-28 Impact factor: 22.113
Authors: Julie Jacobs; Karen Zwaenepoel; Christian Rolfo; Jolien Van den Bossche; Christophe Deben; Karen Silence; Christophe Hermans; Evelien Smits; Paul Van Schil; Filip Lardon; Vanessa Deschoolmeester; Patrick Pauwels Journal: Oncotarget Date: 2015-05-30
Authors: Hyun Min Jung; Rushi S Patel; Brittany L Phillips; Hai Wang; Donald M Cohen; William C Reinhold; Lung-Ji Chang; Li-Jun Yang; Edward K L Chan Journal: Mol Biol Cell Date: 2013-04-03 Impact factor: 4.138
Authors: Mark B Leick; Harrison Silva; Irene Scarfò; Rebecca Larson; Bryan D Choi; Amanda A Bouffard; Kathleen Gallagher; Andrea Schmidts; Stefanie R Bailey; Michael C Kann; Max Jan; Marc Wehrli; Korneel Grauwet; Nora Horick; Matthew J Frigault; Marcela V Maus Journal: Cancer Cell Date: 2022-04-21 Impact factor: 38.585
Authors: Chieko Michikawa; Vancheswaran Gopalakrishnan; Amani M Harrandah; Tatiana V Karpinets; Rekha Rani Garg; Randy A Chu; Yuk Pheel Park; Sasanka S Chukkapallia; Nikhita Yadlapalli; Kelly C Erikson-Carter; Frederico Omar Gleber-Netto; Elias Sayour; Ann Progulske-Fox; Edward K L Chan; Xiaogang Wu; Jianhua Zhang; Christian Jobin; Jennifer A Wargo; Curtis R Pickering; Jeffrey N Myers; Natalie Silver Journal: Neoplasia Date: 2022-07-11 Impact factor: 6.218
Authors: Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang Journal: Mol Carcinog Date: 2020-02-03 Impact factor: 4.784